Cargando…
Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome
We aimed to evaluate the safety and immunogenicity of the BNT162b2 vaccine in young people with Down syndrome (DS), and to compare their humoral immune response with those of the healthy controls (HC). Individuals with DS and HC received the BNT162b2 vaccine. Longitudinal blood samples were collecte...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836979/ https://www.ncbi.nlm.nih.gov/pubmed/35160144 http://dx.doi.org/10.3390/jcm11030694 |
_version_ | 1784649810964381696 |
---|---|
author | Valentini, Diletta Cotugno, Nicola Scoppola, Vittorio Di Camillo, Chiara Colagrossi, Luna Manno, Emma Concetta Perno, Carlo Federico Russo, Cristina Palma, Paolo Rossi, Paolo Villani, Alberto |
author_facet | Valentini, Diletta Cotugno, Nicola Scoppola, Vittorio Di Camillo, Chiara Colagrossi, Luna Manno, Emma Concetta Perno, Carlo Federico Russo, Cristina Palma, Paolo Rossi, Paolo Villani, Alberto |
author_sort | Valentini, Diletta |
collection | PubMed |
description | We aimed to evaluate the safety and immunogenicity of the BNT162b2 vaccine in young people with Down syndrome (DS), and to compare their humoral immune response with those of the healthy controls (HC). Individuals with DS and HC received the BNT162b2 vaccine. Longitudinal blood samples were collected on the day of vaccination, twenty-one days after the first dose, seven days after the second dose, and six months after the first dose. Both the local and systemic adverse events reported by participants were mild. Pain at the injection site was the most reported local adverse event, while fever was the systemic adverse event. Humoral responses showed a significant increase of anti-S and anti-S trimeric antibody (Ab) levels after both doses of vaccine in both groups. In comparison with HC, Ab levels in individuals with DS were similar at T21, but significantly lower, both in terms anti-S and anti-S trimeric, at T28 (respectively p = 0.0003 and p = 0.0001). At T180 both groups showed a significant reduction of anti-S trimeric Ab levels compared to T28 (p = 0.0004 and p < 0.0001 for DS and HC, respectively). Individuals with DS exhibit a good humoral response to the BNT162b2 vaccine; however, similarly to in HC, the immune response wanes over time. |
format | Online Article Text |
id | pubmed-8836979 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88369792022-02-12 Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome Valentini, Diletta Cotugno, Nicola Scoppola, Vittorio Di Camillo, Chiara Colagrossi, Luna Manno, Emma Concetta Perno, Carlo Federico Russo, Cristina Palma, Paolo Rossi, Paolo Villani, Alberto J Clin Med Brief Report We aimed to evaluate the safety and immunogenicity of the BNT162b2 vaccine in young people with Down syndrome (DS), and to compare their humoral immune response with those of the healthy controls (HC). Individuals with DS and HC received the BNT162b2 vaccine. Longitudinal blood samples were collected on the day of vaccination, twenty-one days after the first dose, seven days after the second dose, and six months after the first dose. Both the local and systemic adverse events reported by participants were mild. Pain at the injection site was the most reported local adverse event, while fever was the systemic adverse event. Humoral responses showed a significant increase of anti-S and anti-S trimeric antibody (Ab) levels after both doses of vaccine in both groups. In comparison with HC, Ab levels in individuals with DS were similar at T21, but significantly lower, both in terms anti-S and anti-S trimeric, at T28 (respectively p = 0.0003 and p = 0.0001). At T180 both groups showed a significant reduction of anti-S trimeric Ab levels compared to T28 (p = 0.0004 and p < 0.0001 for DS and HC, respectively). Individuals with DS exhibit a good humoral response to the BNT162b2 vaccine; however, similarly to in HC, the immune response wanes over time. MDPI 2022-01-28 /pmc/articles/PMC8836979/ /pubmed/35160144 http://dx.doi.org/10.3390/jcm11030694 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Valentini, Diletta Cotugno, Nicola Scoppola, Vittorio Di Camillo, Chiara Colagrossi, Luna Manno, Emma Concetta Perno, Carlo Federico Russo, Cristina Palma, Paolo Rossi, Paolo Villani, Alberto Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome |
title | Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome |
title_full | Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome |
title_fullStr | Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome |
title_full_unstemmed | Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome |
title_short | Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome |
title_sort | safety and long-term immunogenicity of bnt162b2 vaccine in individuals with down syndrome |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836979/ https://www.ncbi.nlm.nih.gov/pubmed/35160144 http://dx.doi.org/10.3390/jcm11030694 |
work_keys_str_mv | AT valentinidiletta safetyandlongtermimmunogenicityofbnt162b2vaccineinindividualswithdownsyndrome AT cotugnonicola safetyandlongtermimmunogenicityofbnt162b2vaccineinindividualswithdownsyndrome AT scoppolavittorio safetyandlongtermimmunogenicityofbnt162b2vaccineinindividualswithdownsyndrome AT dicamillochiara safetyandlongtermimmunogenicityofbnt162b2vaccineinindividualswithdownsyndrome AT colagrossiluna safetyandlongtermimmunogenicityofbnt162b2vaccineinindividualswithdownsyndrome AT mannoemmaconcetta safetyandlongtermimmunogenicityofbnt162b2vaccineinindividualswithdownsyndrome AT pernocarlofederico safetyandlongtermimmunogenicityofbnt162b2vaccineinindividualswithdownsyndrome AT russocristina safetyandlongtermimmunogenicityofbnt162b2vaccineinindividualswithdownsyndrome AT palmapaolo safetyandlongtermimmunogenicityofbnt162b2vaccineinindividualswithdownsyndrome AT rossipaolo safetyandlongtermimmunogenicityofbnt162b2vaccineinindividualswithdownsyndrome AT villanialberto safetyandlongtermimmunogenicityofbnt162b2vaccineinindividualswithdownsyndrome |